Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

• Main Authors: Yu-Ting Ma (Author), Yan Li (Author), Li Yan (Author), Fang Hua (Author), Dong-Guan Wang (Author), Guo-Ying Xu (Author), Hong-Lan Yang (Author), Ying-Jie Xue (Author), Ye-Jun Qin (Author), Dan Sha (Author), Hao Ning (Author), Miao-Qing Zhao (Author), Zhi-Gang Yao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1532-2807; 10.3389/pore.2022.1610638
• Keywords: immunotherapy; microsatellite instability; immune checkpoint inhibitors; urothelial carcinoma; lynch syndrome; PD-1/PD-L1; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; Pathology; RB1-214
• Source: Pathology and Oncology Research, Vol 28 (2022)

Immune checkpoint inhibitors (ICIs) have shown encouraging outcomes against Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H). However, there is as yet no clarity on the safety and efficacy of immunotherapy combined with chemotherapy in LS-associated urothelial carcinoma (UC). Here, we report a patient with recurrent and metastatic LS-associated UC who achieved sustained response to programmed death protein 1 (PD-1) inhibitor combined with chemotherapy over 31 months, during which the side effects of immunotherapy could be controlled and managed. Our findings indicate that the dMMR/MSI status and PD-1 expression in UC may have potential predictive value for the response to PD-1-targeted immunotherapy. Our case supports the inclusion of such combination and/or monotherapy for UC in clinical studies and using dMMR/MSI status and PD-1 expression as potential predictive biomarkers for assessment of the therapeutic response.